Sanofi Can't Shake the Generics

Just when Sanofi-Aventis (NYSE: SNY  ) seemed finally free of generic threats against its top drugs, new worries have now popped up. Since Friday, Sanofi's shares have fallen more than 4% after a new potential generic challenger to one of its lead drugs surfaced.

In a press release last week, Swiss generic drug manufacturer Schweizerhall said it was close to receiving final marketing approval in Germany for a version of Sanofi's anti-clotting drug Plavix. Because of European Union rules, if Schweizerhall gets marketing approval from the German health-care authorities, it could eventually market the drug in all of the other EU countries as well.

Sanofi booked 2.4 billion euros in Plavix sales last year, making the drug its second-most-important compound by revenue. The top seller, fellow anticoagulant drug Lovenox, is facing imminent generic pressures of its own.

This would be an unexpected blow to Sanofi, because the main European Plavix patents aren't expected to start expiring until 2013. Schweizerhall didn't say how it would avoid breaking Sanofi's patents on Plavix.

Sanofi and its Plavix marketing partner Bristol-Myers Squibb (NYSE: BMY  ) had to deal with a similar situation in the U.S. in the past two years, after Canadian generic drug manufacturer Apotex briefly flooded the market with generic versions of Plavix. A judge eventually blocked sales of the generic version and upheld Plavix's patents in the U.S.

Every time Sanofi seems to squash generic competition for Plavix or Lovenox, new avenues to attack these drugs always pop up. Sanofi has been mostly successful in escaping generic competition on its lead drugs thus far, but it's still dealing with Plavix patent challenges throughout other parts of the world, including South Korea and Canada. From this Fool's perspective, it seems Schweizerhall may have won the most recent round of Sanofi's ongoing generic wars.

Motley Fool Rule Breakers is always on the hunt for hot drug stocks and other cutting-edge picks. See all of our latest discoveries with a 30-day free trial subscription.

Fool contributor Brian Lawler does not own shares of any company mentioned in this article. The Fool has an A+ disclosure policy.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 644029, ~/Articles/ArticleHandler.aspx, 9/19/2014 2:09:00 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement